Chronic Hepatitis C
Conditions
Keywords
HCV, antiviral, PK, Safety
Brief summary
The purposes of this study are: * to determine the safety and tolerability of multiple doses of A-831 at various doses * to determine how multiple doses of A-831 are distributed through the bloodstream * to determine if A-831 reduces the amount of Hepatitis C virus in the blood
Interventions
DRUGA-831
Sponsors
DDS, Dundee
David Mutimer, Birmingham
Ed Gane, ACS New Zealand
Arrow Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical * Volunteers who have given their written informed consent to participate in the study * Volunteers who are willing and able to comply with the protocol and study procedures * Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection)
Exclusion criteria
* Voulnteers with concurrent medical conditions or taking concurrent medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
| PK | — |
| Tolerability | — |
| Antiviral activity | — |
Countries
New Zealand, United Kingdom
Outcome results
None listed